Comparison of participants who had at least one symptomatic event during the 12-month study period to those who had none
| n | Participants with at least one symptomatic episode (n=62) | n | Participants with no documented symptomatic episode (n=16) | p | |
| Age at enrolment | 62 | 4.4 (3.5–5.2) | 16 | 3.8 (3.6–5.2) | 0.63 |
| Male sex | 62 | 32 (51.6) | 16 | 7 (43.8) | 0.39 |
| LCI at enrolment | 43 | 8.8 (8.3–9.3) | 8 | 8.6 (7.0–10.2) | 0.71 |
| zFEV1 at enrolment | 27 | −0.41 (−1.1 to 0.1) | 3 | −0.41 (−1.4 to 0.43) | 0.54 |
| BMI centile* at enrolment | 62 | 48.0 (40.1–55.0) | 16 | 45.4 (33.2–57.6) | 0.73 |
| Ever hospitalised | 62 | 35 (55.5) | 16 | 6 (40.0) | 0.28 |
| Genotype | |||||
| Class I–III | 62 | 60 (96.8) | 16 | 15 (93.8) | 0.50 |
| Class IV–V | 62 | 2 (3.2) | 16 | 1 (6.3) | 0.50 |
| Maintenance therapy at enrolment | |||||
| Hypertonic saline | 62 | 32 (51.6) | 16 | 6 (37.5) | 0.40 |
| Dornase alpha | 62 | 26 (41.9) | 16 | 7 (43.8) | 1.00 |
| Chronic inhaled antibiotics | 62 | 13 (21.0) | 16 | 5 (31.3) | 0.51 |
| Sputum/oropharyngeal swab microbiology (ever positive in 12 months prior to study) | |||||
| Methicillin sensitive Staphylococcus aureus | 62 | 55 (88.7) | 16 | 13 (81.3) | 0.42 |
| Pseudomonas aeruginosa | 62 | 38 (61.3) | 16 | 8 (50.0) | 0.57 |
| Haemophilus influenzae | 62 | 33 (53.2) | 16 | 7 (43.8) | 0.58 |
| Stenotrophomonas maltophilia | 62 | 13 (21.0) | 16 | 3 (18.8) | 1.00 |
| Methicillin-resistant Staphylococcus aureus | 62 | 10 (16.1) | 16 | 1 (6.3) | 0.44 |
| Burkholderia cepacia complex | 62 | 0 (0) | 16 | 2 (12.5) | 0.04 |
Data are presented as median (IQR) or number (%) as appropriate unless otherwise stated. P values for Wilcoxon rank-sum or Fisher’s exact tests are shown.
*Based on CDC growth chart.
Data acquired at the enrolment visit are shown.
BMI, body mass index; LCI, lung clearance index; zFEV1, z-score for FEV1.